Absolute Antibody provides recombinant antibody products and services to customers around the world for pharmaceutical, diagnostic and research applications. Below are case studies and testimonials illustrating the benefits of our recombinant antibody technology.
Saving a Malaria Antibody with Therapeutic Potential
Dr. Jake Kurtis, Professor of Pathology and Laboratory Medicine at Brown University, had to abandon a promising anti-malaria antibody after the hybridoma stopped expressing. Absolute Antibody was able to recover the antibody sequence, produce a high-performing recombinant version, and develop humanized variants. “Working with Absolute Antibody was super simple,” Dr. Kurtis said. “Turnaround time was fast, the deliverables and written reports were very helpful, and the team successfully addressed all my questions about the sequence.”
Optimizing an Antibody for Glioblastoma Treatment
Dr. Mariano Viapiano of the State University of New York had developed an antibody that successfully treated glioblastoma in mouse models. Absolute Antibody provided recombinant production, chimerization and finally humanization services to develop optimized humanized antibodies with the robust manufacturability required for clinical use. ““I would absolutely recommend Absolute Antibody to another researcher,” Dr. Viapiano said. “I was kept informed of the project at each step and milestone, and the team is very efficient. Whenever they said they’re making X antibody with X features, that’s exactly what we got.”
Using Bispecific Antibody Reagents to Further Immunotherapy Research
Researchers at the Leiden University Medical Center (LUMC) in the Netherlands used Absolute Antibody’s unique murine knob-into-hole (KIH) bispecific antibody reagents to treat cancer in mouse models. The study demonstrated that T-cell-engaging CD3ε-bispecific antibodies in combination with oncolytic viruses could improve immunotherapy treatment of solid cancer tumors.
Engineered, Species-Matched Antibody Allowed for Long-Term CD8+ T-Cell Depletion in Mice
Prof. Daniel Pinschewer at the University of Basel in Switzerland was able to successfully deplete CD8+ T-cells long-term using Absolute Antibody’s recombinant anti-CD8 depletion antibody, which was engineered to have mouse IgG2a constant domains especially suited to in vivo work. Dr. Pinschewer’s team established in mouse experiments that the chimeric antibody depleted CD8+ T-cells to below detection limits in blood for at least two months, thus for much longer periods of time than ever previously observed with the standard rat anti-CD8 antibody.
Saving CP9/19: An Antibody Sequencing Story
“The antibody CP9/19 was first characterized almost 30 years ago… It was of grave concern to Ximbio when we learnt that the rat hybridoma cells were contaminated with mouse antibody producing cells which were much more proliferative but as yet unknown. The Absolute Antibody team excelled in this project, firstly to ensure the longevity of this antibody through sequencing and secondly to enable the generation of an antibody preparation that is superior in performance to one derived from the hybridoma.” – Ximbio portfolio team member at the time of this project
Engineering a DNA/RNA G-quadruplex Antibody
The laboratory of Dr. Shankar Balasubramanian at the University of Cambridge had developed a single-chain variable fragment (scFv) antibody to detect DNA/RNA G-quadruplex. Absolute Antibody used the sequence of the antibody clone to engineer four new formats: full-length mouse IgG1, mouse Fab fragment, full-length goat IgG and human Fab fragment. All new versions were produced recombinantly and shown to effectively bind DNA/RNA G-quadruplex; they have now been used successfully by researchers around the world.